oxaliplatin / Generic mfg. 
Welcome,         Profile    Billing    Logout  

382 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
oxaliplatin / Generic mfg.
DeFianCe, NCT05480306: Phase 2 Study of DKN-01 in Colorectal Cancer

Hourglass Oct 2023 - Mar 2024 : Initial PFS data from DeFianCe trial in combination with bevacizumab and chemotherapy for colorectal cancer
Hourglass Jul 2023 - Sep 2023 : Initial ORR data from DeFianCe trial in combination with bevacizumab and chemotherapy for colorectal cancer
Recruiting
2
200
Europe, US, RoW
DKN-01, LY2812176, FOLFIRI, Bevacizumab, FOLFOX
Leap Therapeutics, Inc.
Colorectal Cancer, Colorectal Adenocarcinoma, Colo-rectal Cancer, Colorectal Cancer Metastatic
10/25
10/25
NCT06247956: Study of SHR-8068 Combined With Adebrelimab and Platinum-containing Chemotherapy in the Treatment of Advanced Gastric and Esophageal Cancer

Recruiting
2
120
RoW
SHR-8068;Adebrelimab;Oxaliplatin;Capecitabine Tablets;Paclitaxel Injection;Cisplatin Injection, Adebrelimab;Oxaliplatin;Capecitabine Tablets;Paclitaxel Injection;Cisplatin Injection
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Advanced Gastric Adenocarcinoma and Esophageal Squamous Cell Carcinoma
02/25
08/25
NCT06208462: Neoadjuvant Therapy of HAIC（GEMOX） Combined With Adebrelimab and Lenvatinib for Resectable Intrahepatic Cholangiocarcinoma With High-risk Recurrence Factors

Recruiting
2
33
RoW
Adebrelimab, SHR-1316, Lenvatinib, 4-{3-chloro-4-[(cyclopropylcarbamoyl)amino]phenoxy}-7-methoxyquinoline-6-carboxamide, Gemcitabine, Difluorodeoxycytidine Hydrochloride, Oxaliplatin, Diaminocyclohexane Oxalatoplatinum
The First Affiliated Hospital with Nanjing Medical University, Jiangsu Hengrui Pharmaceutical Co., Ltd.
Intrahepatic Cholangiocarcinoma
01/26
01/27
REVISE, NCT06242418: ctDNA in Adjuvant Chemotherapy of Stage III Colon Cancer ( Trial)

Recruiting
2
60
RoW
FOLFOXIRI, XELOX
West China Hospital, GeneCast Biotechnology Co., Ltd.
Colon Cancer
12/25
12/26
NCT05799820: QL1706 Monotherapy or in Combination With Bevacizumab and XELOX as First-line Treatment of Unresectable Advanced or Metastatic CRC

Recruiting
2
60
RoW
QL1706, Bevacizumab, Oxaliplatin injection, Capecitabine
Qilu Pharmaceutical Co., Ltd.
Colorectal Carcinoma
03/24
09/25
NCT06320301: Adebrelimab and a TKI in Combination With GEMOX in First-line Treatment of Advanced Biliary Tract Cancers (BTC)

Recruiting
2
43
RoW
Adebrelimab + GEMOX + TKI, Adebrelimab+ tyrosine kinase inhibitor (TKI) + gemcitabine - oxaliplatin (GEMOX)
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Biliary Tract Cancer, Gemox Chemotherapy
02/26
06/26
NCT06283121: A Clinical Study of BioTTT001 in Combination With SOX and Toripalimab in Patients With Gastric Cancer

Not yet recruiting
2
30
NA
BioTTT001 intraperitoneal infusion, SOX regimen, toripalimab
China Medical University, China, Beijing Bio-Targeting Therapeutics Technology Co., Ltd
Gastric Cancer, Metastatic
11/27
11/27
NCT03488667: Perioperative mFOLFOX Plus Pembrolizumab in Gastroesophageal Junction (GEJ) and Stomach Adenocarcinoma

Active, not recruiting
2
40
US
Neoadjuvant Treatment - mFOLFOX6 & Pembrolizumab, Adjuvant Treatment - mFOLFOX & Pembrolizumab
University of Kansas Medical Center, Merck Sharp & Dohme LLC
Gastro Esophageal Junction Cancer, Stomach Cancer, Adenocarcinoma
04/24
04/25
Pan-MSI-ACSE, NCT06333314: Dostarlimab for Locally Advanced or Metastatic Cancer (Non-colorectal/Non-endometrial) With Tumor dMMR/MSI

Not yet recruiting
2
120
Europe
Dostarlimab, Chemotherapy
UNICANCER, National Cancer Institute, France, GlaxoSmithKline
Pancreatic Adenocarcinoma, Ampulla of Vater Carcinoma, Adrenocortical Carcinoma, Neuroendocrine Carcinoma, Soft Tissue Sarcoma, Small Bowel Adenocarcinoma, Duodenum Adenocarcinoma, Gastric Adenocarcinoma
10/28
09/30
daNIS-3, NCT04952753 / 2021-000553-40: Study of NIS793 and Other Novel Investigational Combinations With SOC Anti-cancer Therapy for the 2L Treatment of mCRC

Active, not recruiting
2
204
Europe, Canada, Japan, US, RoW
NIS793, Bevacizumab, Modified FOLFOX6, 5FU+Leucovorin+Oxaliplatin, FOLFIRI, 5FU+Leucovorin+Irinotecan, Tislelizumab, VDT482
Novartis Pharmaceuticals, Novartis Pharma AG
Metastatic Colorectal Cancer
09/24
09/24
NCT06475417: Neoadjuvant Adebrelimab + DOS in Locally Advanced Resectable Gastric Cancer

Recruiting
2
42
RoW
Adebrelimab combined with DOS
Tang-Du Hospital, Jiangsu Hengrui Pharmaceutical Co., Ltd.
Gastric Cancer
05/25
04/26
TRIPP-FFX, NCT05466799: FOLFIRINOX Versus OncoSil™ in Addition to FOLFIRINOX in Patients With Locally Advanced Pancreatic Adenocarcinoma

Recruiting
2
80
Europe, RoW
FOLFIRINOX chemotherapy, Folinic Acid, 5-FU, Oxaliplatin, Irinotecan, OncoSil™, Phosphorous-32 microparticles
OncoSil Medical Limited
Locally Advanced Pancreatic Cancer
06/24
09/24
CCGLC-013, NCT06192797: Combined HAIC, Lenvatinib and Pucotenlimab as Conversion Therapy for Unresectable Intrahepatic Cholangiocarcinoma

Recruiting
2
36
RoW
HAIC, hepatic arterial infusion chemotherapy of GEMOX, Lenvatinib plus pucotenlimab, levima plus pucotenlimab
Ze-yang Ding, MD, Geneplus-Beijing Co. Ltd., Chinese Cooperative Group of Liver Cancer
Cholangiocarcinoma Non-resectable
12/25
06/26
TRIFLUOX-DP, NCT06245356: Safety of Trifluridine/Tipiracil in Patients With Dihydropyrimidine Dehydrogenase Deficiency Diagnosed With Metastatic Colorectal or Gastroesophageal Cancer

Not yet recruiting
2
73
NA
Lonsurf, Oxaliplatin, Panitumumab, Bevacizumab, Trastuzumab, Nivolumab
UNICANCER, Servier
Metastatic Colorectal Cancer, Metastatic Gastroesophageal Adenocarcinoma, DPD Deficiency
06/26
06/28
NCT05099848: A Trial of Conversion Treatment of HAIC Combined With Camrelizumab and Apatinib for Unresected Hepatocellular Carcinoma

Active, not recruiting
2
21
RoW
Camrelizumab, Apatinib, FOLFOX Protocol (Oxaliplatin, fluorouracil, and leucovorin); Camrelizumab for injection and Apatinib-Mesylate Tablets
Shandong Cancer Hospital and Institute, Jiangsu HengRui Medicine Co., Ltd.
Hepatocellular Carcinoma
06/24
12/24
QLS31905-202, NCT06446388: Study of QLS31905 and/or QL1706 Combination With Chemotherapy in the Advanced Malignant Solid Tumors

Not yet recruiting
2
360
RoW
QLS31905, Oxaliplatin, Capecitabine, Gemcitabine, Cisplatin, QL1706, Chemotherapy drug
Qilu Pharmaceutical Co., Ltd.
Advanced Solid Tumor
06/26
12/27
NCT04947826: Combination Therapy of HAIC and HLX10 and HLX04 in HCC With Major Portal Vein Tumor Thrombosis

Not yet recruiting
2
100
NA
HAIC (Hepatic arterial infusion chemotherapy), HLX10 (PD-1 antibody), HLX04 (VEGF antibody), Placebo
Shanghai Zhongshan Hospital, Shanghai Henlius Biotech
Hepatocellular Carcinoma With Major Portal Vein Thrombosis
07/24
07/24
BBOpCo, NCT06268015: Botensilimab and Balstilimab Optimization in Colorectal Cancer

Not yet recruiting
2
15
US
Botensilimab, Balstilimab, Oxaliplatin, Leucovorin, Fluorouracil, Bevacizumab, Panitumumab
Nicholas DeVito, MD, Gateway for Cancer Research, Agenus Inc.
Colorectal Cancer
07/28
07/28
PEGASUS, NCT04259944: Post-surgical Liquid Biopsy-guided Treatment of Stage III and High-risk Stage II Colon Cancer Patients: the Trial

Active, not recruiting
2
140
Europe
CAPOX, Capecitabine, FOLFIRI
IFOM ETS - The AIRC Institute of Molecular Oncology, Guardant Health, Inc.
Colon Cancer
07/24
10/24
NCT05300269: SHR-1701 in Combination With Chemotherapy and Radiotherapy in Locally Advanced Rectal Cancer

Recruiting
2
73
RoW
SHR-1701；Capecitabine；Oxaliplatin
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Locally Advanced Rectal Cancer
07/24
10/26
NeoBRAF, NCT05510895: Neoadjuvant Encorafenib, Binimetinib and Cetuximab for Patients With BRAF V600E Mutated/pMMR Localized Colorectal Cancer

Recruiting
2
48
Europe
Binimetinib, Encorafenib, Cetuximab
AIO-Studien-gGmbH, Pierre Fabre Pharma GmbH, Merck Serono GmbH, Germany, Universitätsklinikum Hamburg-Eppendorf
Colorectal Cancer, Colon Cancer, BRAF V600E, BRAF V600 Mutation, Localized Cancer
07/24
01/25
LyRICX, NCT03764553: Liposomal iRInotecan, Carboplatin or oXaliplatin for Esophagogastric Cancer

Recruiting
2
310
Europe
Liposomal Irinotecan, Carboplatin, Capecitabine, Xeloda, Oxaliplatin, 5-fluorouracil, Leucovorin
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA), Servier
Esophageal Cancer
08/24
08/24
NCT03984578: Window of Opportunity Study in Colorectal Cancer

Recruiting
2
50
RoW
CAPEOX, Pembrolizumab, Keytruda, Capecitabine/ 5-FU, CAPEOX/Pembrolizumab, Pembrolizumab alone, Surgical resection
National Cancer Centre, Singapore, Merck Sharp & Dohme LLC
Colorectal Cancer
08/24
08/24
NCT05511051: A Prospective Multi-centered Randomized Controlled Trial on Fruquintinib in Combination With HAIC in the Treatment of Liver Metastatic Colorectal Cancer After Failure of Second-line Systematic Therapy

Recruiting
2
102
RoW
Fruquintinib, HAIC
Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Hutchison Medipharma Limited
Colorectal Cancer
08/24
12/24
IIT2022-11-Gangi-SAMe, NCT06258525: SAMe in Prevention of Oxaliplatin-associated Liver Injury

Not yet recruiting
2
30
US
Standard of care oxaliplatin-based chemotherapy, S-adenosylmethionine (SAMe) supplement, Surgery
Cedars-Sinai Medical Center, Jarrow Formulas Inc
Colorectal Cancer, Liver Metastases, Liver Metastasis Colon Cancer, Liver Injury, Sinusoidal Obstruction Syndrome, 5-Fluorouracil Toxicity, Liver Toxicity, Chemically-Induced
10/26
10/26
NCT05960955: Cadonilimab Combination With Chemotherapy With or Without AK117 in Resectable Gastric or Gastroesophageal Junction Adenocarcinoma

Recruiting
2
90
RoW
Cadonilimab, AK117, Oxaliplatin, Tegafur-gimeracil-oteracil potassium, Docetaxel, 5-Fluorouracil
Akeso
Resectable Gastric or Gastroesophageal Junction Adenocarcinoma
11/24
11/27
NCT04169347: FOLFOXIRI Plus Panitumumab in Metastatic RAS Wild-type, Left-sided Colorectal Cancer

Active, not recruiting
2
27
US
Oxaliplatin, Irinotecan, Leucovorin, Panitumumab
Criterium, Inc., Amgen
Colorectal Cancer Metastatic
12/24
01/25
EXPLORING, NCT05494060: XELOX Combined With Anlotinib and Penpulimab vs XELOX as Adjuvant Therapy in ctDNA Positive Gastric and Esophagogastric Junction Adenocarcinoma

Recruiting
2
80
RoW
Anlotinib hydrochloride capsule, Penpulimab Injection, AK-105, XELOX, Capecitabine and Oxaliplatin
The First Affiliated Hospital with Nanjing Medical University, Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Carcinoma, Gastrointestinal Diseases, Stomach Cancer, Gastroesophageal-junction Cancer, Digestive System Diseases, Gastric Cancer, Gastrointestinal Neoplasms
12/24
02/27
NCT05630183: A Study of Botensilimab in Participants With Metastatic Pancreatic Cancer

Hourglass Jan 2024 - Jun 2024 : Results from C-800-22 trial for 2L metastatic pancreatic cancer
Recruiting
2
78
US
Botensilimab, AGEN1181, Gemcitabine, Nab-paclitaxel
Agenus Inc.
Metastatic Pancreatic Ductal Adenocarcinoma
12/24
12/24
DUREC, NCT04293419: Durvalumab (MEDI4736) Plus Total Neoadjuvant Therapy (TNT) in Locally Advanced Rectal Cancer

Recruiting
2
58
Europe
Durvalumab (MEDI4736)
Grupo Espanol Multidisciplinario del Cancer Digestivo, AstraZeneca, Vall d'Hebron Institute of Oncology (VHIO)
Rectal Cancer
12/24
03/25
HOLIPANC, NCT04617457: Chemotherapy and Surgical Resection in Patients With Hepatic Oligometastatic Adenocarcinoma of the Pancreas

Recruiting
2
150
Europe
nal-irinotecan (nal-iri) (Onyvide), oxaliplatin (ox), 5-fluouracil (5-FU), folinic acid (FA), nal-irinotecan (nal-iri), oxaliplatin (ox), 5-fluouracil (5-FU), folinic acid (FA), ONIVYDE TM
University of Cologne, Servier
Pancreatic Cancer, Metastasis, Surgery, Oligometastatic Disease
12/24
09/25
LOTS, NCT04999332: Perioperative Leucovorin, Oxaliplatin, Docetaxel and S-1 () For Locally Advanced Gastric or Gastroesophageal Junction Cancer

Recruiting
2
58
RoW
leucovorin, oxaliplatin, docetaxel, S-1, leucovorin (Folina tab, TTY Biopharm, TW), oxaliplatin (Oxalip, TTY Biopharm, TW), docetaxel (Taxotere, Sanofi-Aventis, FR), S-1 (TS-1, Taiho, JP)
National Cheng-Kung University Hospital, TTY Biopharm, Kaohsiung Veterans General Hospital., Taipei Veterans General Hospital, Taiwan, China Medical University Hospital
Gastric Cancer, Gastric Adenocarcinoma, Effects of Chemotherapy, Toxicity Due to Chemotherapy
12/24
12/25
NCT05945823: Phase 2 Futibatinib in Combination With PD-1 Antibody Based Standard of Care in Solid Tumors

Recruiting
2
66
Europe, US
Futibatinib, TAS-120, Pembrolizumab, MK-3475, KEYTRUDA®, Cisplatin, PLATINOL®, 5-FU, ADRUCIL®, Oxaliplatin, ELOXATIN®, Leucovorin, calcium folinate, folinic acid, WELLCOVORIN®, Levoleucovorin, calcium levofolinate, levofolinic acid, FUSILEV®, Irinotecan
Taiho Oncology, Inc.
Locally Advanced Unresectable or Metastatic Solid Tumors Including Esophageal Cancer, Esophageal Adenocarcinoma, Esophageal Squamous Cell Cancer, Siewert Type 1 GEJ Cancer, Pancreatic Cancer
01/25
05/25
ILUSTRO, NCT03505320 / 2017-002566-50: A Study to Assess the Antitumor Activity, Safety, Pharmacokinetics and Biomarkers of Zolbetuximab (IMAB362) in Participants With Claudin (CLDN) 18.2 Positive, Metastatic or Advanced Unresectable Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma and Locoregional Gastric or GEJ Adenocarcinoma

Recruiting
2
143
Europe, Japan, US, RoW
zolbetuximab, IMAB362, oxaliplatin, leucovorin, fluorouracil, Pembrolizumab, folinic acid, nivolumab, Docetaxel
Astellas Pharma Global Development, Inc.
Pharmacokinetics of Zolbetuximab, Gastric Cancer, Gastro-esophageal Junction (GEJ) Cancer, Pharmacokinetics of Oxaliplatin, Pharmacokinetics of Fluorouracil Bolus (5-FU)
04/25
12/26
AuspiCiOus, NCT05177133: Anti-PD-1 and CapOx for the First-line Treatment of dMMR Esophagogastric Cancer

Recruiting
2
25
Europe
Capecitabine, Xeloda, Oxaliplatin, Oxaliplatin Accord, Retifanlimab, INCMGA00012
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA), Incyte Corporation
Gastric Adenocarcinoma, Esophageal Adenocarcinoma
05/25
11/29
DisTinGuish, NCT04363801: A Study of DKN-01 in Combination With Tislelizumab ± Chemotherapy in Patients With Gastric or Gastroesophageal Cancer

Hourglass Oct 2023 - Mar 2024 : Q4'23/Q1'24 - Initial ORR data from DisTinGuish trial for 2L gastric cancer
Oct 2023 - Dec 2023: Initial data from part C of DisTinGuish trial in combination with tislelizumab for 1L gastric cancer
Checkmark Updated data from part B of DisTinGuish trial in combination with tislelizumab for 2L gastric cancer
Nov 2022 - Nov 2022: Updated data from part B of DisTinGuish trial in combination with tislelizumab for 2L gastric cancer
Checkmark ORR, PFS and OS data from DisTinGuish trial in combination with tislelizumab for gastroesophageal junction cancer or gastric cancer
More
Active, not recruiting
2
232
Europe, US, RoW
DKN-01 300mg, DKN-01 600mg, DKN-01 400mg, Tislelizumab 200mg, Tislelizumab 400mg, Oxaliplatin, Capecitabine 1000mg/ m2 BID, Xeloda, Leucovorin Calcium, Folinic acid, Fluorouracil
Leap Therapeutics, Inc., BeiGene
Gastric Cancer, Gastric Adenocarcinoma, GastroEsophageal Cancer
06/25
12/25
PRIME-RT, NCT04621370: A Trial of Durvalumab (MEDI 4736) in Combination With Extended Neoadjuvant Regimens in Rectal Cancer

Not yet recruiting
2
48
NA
Durvalumab, MEDI 4736, FOLFOX, mFOLFOX6, Short Course Radiotherapy (Arm A), Long course chemoradiation (Arm B), Capecitabine
Liz-Anne Lewsley, University of Glasgow, AstraZeneca, NHS Greater Glasgow and Clyde
Rectal Cancer, Rectal Adenocarcinoma, Rectal Neoplasms
06/25
12/25
EPOC2001, NCT04745988: An Open Label Phase 2 Study to Evaluate the Safety and Efficacy of Lenvatinib With Pembrolizumab or Lenvatinib, Pembrolizumab and FLOT in the Neoadjuvant / Adjuvant Treatment for Patients With Gastric Cancer

Recruiting
2
43
Japan
Lenvatinib 20mg, Pembrolizumab, Lenvatinib 8mg, Docetaxel, Oxaliplatin, Levofolinate, Fluorouracil
National Cancer Center Hospital East, Merck Sharp & Dohme LLC
Gastric Cancer
08/25
08/27
CA209-8TT, NCT03899155 / 2018-004362-34: Pan Tumor Rollover Study

Recruiting
2
1500
Europe, Canada, Japan, US, RoW
Nivolumab, BMS-936558-01, Ipilimumab, Cabozantinib, Trametinib, Relatlimab, BMS-986016-01, Nivolumab + Relatlimab, BMS-986213, Capecitabine, Bevacizumab, Temozolomide, Rucaparib, Daratumumab, Regorafinib, Leucovorin, Fluorouracil, Oxaliplatin, Enzalutamide, Sunitinib, Pemetrexed, Pembrolizumab
Bristol-Myers Squibb, Exelixis, Novartis, Clovis Oncology, Inc., Janssen Pharmaceuticals
Cancer
08/29
08/29
EDGE-Gastric, NCT05329766: A Safety and Efficacy Study of Treatment Combinations With and Without Chemotherapy in Adult Participants With Advanced Upper Gastrointestinal Tract Malignancies

Calendar Jan 2023 - Dec 2024: Data from ARC-21 trial for esophageal adenocarcinoma, gastroesophageal junction and gastric adenocarcinoma
Recruiting
2
360
Europe, Canada, US, RoW
Domvanalimab, Quemliclustat, Zimberelimab, Fluorouracil, Leucovorin, Oxaliplatin
Arcus Biosciences, Inc., Gilead Sciences
Gastrointestinal Tract Malignancies
09/26
06/27
DESTINY-Gastric03, NCT04379596: Ph1b/2 Study of the Safety and Efficacy of T-DXd Combinations in Advanced HER2-expressing Gastric Cancer

Jul 2023 - Dec 2023: Data from DESTINY-Gastric03 trial for gastric cancer
Checkmark Presentation of data from DESTINY-Gastric03 study in HER2-overexpressing gastric cancer at ESMO 2020
Jul 2020 - Jul 2020: Presentation of data from DESTINY-Gastric03 study in HER2-overexpressing gastric cancer at ESMO 2020
Recruiting
2
413
Europe, Canada, Japan, US, RoW
Fluorouracil (5-FU), Capecitabine, Durvalumab, MEDI4736, Oxaliplatin, Trastuzumab, Trastuzumab deruxtecan, DS-8201a, Cisplatin, Pembrolizumab, Volrustomig, MEDI5752, Rilvegostomig, AZD2936
AstraZeneca, Daiichi Sankyo Company, Limited 3-5-1 Nihonbashihoncho, Chuo-ku, Tokyo
Gastric Cancer
07/26
07/26
GEMINI-Gastric, NCT05702229 / 2022-002840-29: Novel Combinations in Participants With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma

Recruiting
2
240
Europe, Japan, US, RoW
Rilvegostomig, Volrustomig, FOLFOX, XELOX, AZD7789, AZD0901, 5-Fluorouracil, Capecitabine
AstraZeneca, AstraZeneca AB
Gastric Cancer
09/25
03/26
ERASE-CRC, NCT05062889: Exploiting Circulating Tumour DNA to Intensify the Postoperative Treatment Resected Colon Cancer Patients

Recruiting
2
477
Europe
5-Fluorouracil continuous infusion FOLFOXIRI schedule, 5FU, 5-Fluorouracil bolus FOLFOX schedule, 5-Fluorouracil continuous infusion FOLFOX schedule, Oxaliplatin FOLFOX and FOLFOXIRI schedule, Oxa, Oxaliplatin CAPOX schedule, L-Leucovorin, Lederfolin, Capecitabine, Irinotecan, Trifluridine/Tipiracil, FTD/TPI, Trastuzumab, Tucatinib
Gruppo Oncologico del Nord-Ovest, Servier, Foundation Medicine, Seagen Inc.
Stage II Colon Cancer, Stage III Colon Cancer, HER2-positive Colon Cancer, RAS Wild-type Colon Cancer
10/25
12/27
NCT05239650: Phase II Clinical Study to Evaluate the Efficacy and Safety of HLX07+HLX10 +mFOLFOX6 or HLX07 Monotherapy in Patients With mCRC

Not yet recruiting
2
50
NA
HLX07, HLX10, mFOLFOX6
Shanghai Henlius Biotech
CRC
10/25
10/26
ZWI-ZW25-201, NCT03929666: A Safety and Efficacy Study of ZW25 (Zanidatamab) Plus Combination Chemotherapy in HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal Cancer

Active, not recruiting
2
74
Canada, US, RoW
ZW25 (Zanidatamab), Capecitabine, Cisplatin, Fluorouracil, Leucovorin, Oxaliplatin, Bevacizumab, Gemcitabine
Jazz Pharmaceuticals
HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal Cancer
11/25
10/26
BOLSTER, NCT05712356: A Study of LSTA1 When Added to Standard of Care Versus Standard of Care Alone in Patients With Advanced Solid Tumors

Recruiting
2
80
Europe, US
LSTA1, Durvalumab, Cisplatin, Gemcitabine, FOLFOX regimen, Oxaliplatin, Folinic acid, Fluorouracil, Placebo
Lisata Therapeutics, Inc.
Cholangiocarcinoma, Gallbladder Cancer, Gallbladder Carcinoma, Intrahepatic Cholangiocarcinoma, Extrahepatic Cholangiocarcinoma, Bile Duct Cancer, Gall Bladder Cancer, Gall Bladder Carcinoma
12/25
12/25
LOGICAN, NCT05476796: Oxaliplatin ± Nivolumab in Combination With Trifluridine/Tipiracil or 5-fluorouracile in Frail Patients With Advanced, Recurrent or Metastatic Gastric, Oesophageal or Gastroesophageal Junction Cancer

Recruiting
2
118
Europe
Trifluridine/Tipiracil, Lonsurf, Oxaliplatin, FOLFOX regimen, Nivolumab, OPDIVO
UNICANCER, Servier
Gastric Adenocarcinoma, Esophagus Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
01/26
01/27
NCT04162665: Pre-operative Adaptive Short Court Radiation Therapy in Gastric Cancer

Recruiting
2
36
US, RoW
Adaptive short course radiation therapy, Standard of care chemotherapy regimen
Washington University School of Medicine, Viewray Inc.
Gastric Adenocarcinoma
04/26
04/27
NCT05851924: A Study of NALIRIFOX in Combination With Radiation Therapy in People With Pancreatic Ductal Adenocarcinoma (PDAC)

Recruiting
2
60
US
NALIRIFOX, AD-XRT and Capecitabine
Memorial Sloan Kettering Cancer Center, Ipsen, Pancreatic Cancer Research Fund
Pancreatic Ductal Adenocarcinoma
05/26
05/26
NCT05864105: PM8002 in Combination With Chemotherapy as First Line Therapy in Hepatocellular Carcinoma

Recruiting
2
35
RoW
PM8002, FOLFOX regimen
Biotheus Inc.
Hepatocellular Carcinoma
06/26
06/26
NCT05671822: Ph1b/2 Study of the Safety and Efficacy of SHR-A1811 Combinations in Advanced HER2+ Gastric Cancer

Recruiting
2
156
RoW
SHR-A1811；SHR-1701；capecitabine；oxaliplatin
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
HER2+ Gastric Cancer/Gastroesophageal Junction Adenocarcinoma
07/26
07/26
NCT05983367: A Study to Investigate Ompenaclid Combined With FOLFIRI Plus Bevacizumab in Advanced/Metastatic Colorectal Cancer

Recruiting
2
70
Europe
Ompenaclid (RGX-202), Placebo, Bevacizumab, FOLFIRI regimen
Inspirna, Inc.
Colorectal Cancer, Metastatic Colon Cancer
08/26
08/28
NCT05870800: Neoadjuvant Chemoimmunotherapy for Resectable Non-Metastatic Proficient Mismatch Repair (PMMR) Colon Cancer

Not yet recruiting
2
30
US
Tecentriq 1200 MG in 20 ML Injection + Capecitabine 1000 mg/m2 + Oxaliplatin 130 mg/m2, Neoadjuvant Chemoimmunotherapy, Oxaliplatin injection 85mg/m2 + Leucovorin 400mg/m2 + 5-Fluorouracil 2400mg/m2, mFOLFOX6, Oxaliplatin 130mg/m2 + Capecitabine 1000mg/m2, CAPEOX
Baylor College of Medicine, Genentech, Inc.
Stage I Colon Cancer, Stage II Colon Cancer, Stage III Colon Cancer
09/26
01/28
NCT06106308: Study of Onvansertib in Combination With FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab Versus FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab for First-Line Treatment of Metastatic Colorectal Cancer in Adult Participants With a KRAS or NRAS Mutation

Recruiting
2
90
US
Onvansertib, FOLFIRI, Bevacizumab, FOLFOX
Cardiff Oncology, Pfizer
Metastatic Colorectal Cancer, CRC, KRAS/NRAS Mutation
11/26
01/27
ANTONIO, NCT05118724: Atezolizumab in Patients With MSI-h/MMR-D Stage III Colorectal Cancer Ineligible for Oxaliplatin

Recruiting
2
80
Europe
Atezolizumab, Tecentriq
AIO-Studien-gGmbH, Roche Pharma AG, Immodulon Therapeutics Ltd
Colorectal Cancer
11/26
11/26
NCT04566380: ONO-4538 Phase II Rollover Study (ONO-4538-98)

Recruiting
2
59
Japan, RoW
ONO-4538, oxaliplatin, S-1, capecitabine, bevacizumab, temozolomide
Ono Pharmaceutical Co. Ltd
Pan-tumor
12/26
12/26
ChiCTR2200056870: An open, multicenter, single-arm, phase II study evaluating triplimumab injection (JS001) combined with chemotherapy for neoadjuvant treatment of gastric/gastroesophageal junction cancer

Not yet recruiting
2
40
China
Toripalimab injection (JS001) combined with capecitabine and oxaliplatin
Guangdong Provincial People's Hospital ; Guangdong Provincial People's Hospital, Tririplizumab injection (JS001) was provided free of charge by Shanghai Junshi Biomedical Technology Co., LTD.
gastric/gastroesophageal junction carcinoma
 
 
KEYVIBE-005, NCT05007106 / 2021-001009-56: MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005)

Recruiting
2
610
Europe, Canada, Japan, US, RoW
Pembrolizumab/Vibostolimab Co-Formulation, MK-7684A, Pembrolizumab, MK-3475, KEYTRUDA®, Lenvatinib, Lenvima, E7080, MK-7902, 5-Fluorouracil, 5-FU, Fluracil, Cisplatin, Platinol, cis Platinum, Paclitaxel, Taxol, Abraxane, Anzatax, Gemcitabine, Carboplatin, Docetaxel, Bevacizumab, Capecitabine, Oxaliplatin
Merck Sharp & Dohme LLC, Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Merck Sharp & Dohme LLC
Uterine Cervical Neoplasms, Endometrial Neoplasms, Squamous Cell Carcinoma of Head and Neck, Gallbladder Neoplasms, Cholangiocarcinoma, Esophageal Neoplasms, Triple Negative Breast Neoplasms, Hepatocellular Carcinoma, Urinary Bladder Neoplasms, Ovarian Neoplasms, Stomach Neoplasms
02/27
02/27
AIRPanc, NCT06048484: Combination Therapy in Patients With Localized Pancreatic Ductal Adenocarcinoma

Recruiting
2
60
US
Stereotactic body radiotherapy (SBRT), Zimberelimab, AB122, Quemliclustat, AB680, Etrumadenant, AB928, Modified FOLFIRINOX, mFOLFIRINOX
Gulam Manji, Arcus Biosciences, Inc.
Pancreatic Ductal Adenocarcinoma
04/27
04/27
DANTE, NCT03421288 / 2017-001979-23: Study of Atezolizumab + FLOT vs. FLOT Alone in Patients With GC/GEJ and High Immune Responsiveness

Recruiting
2
674
Europe
Atezolizumab, TECENTRIQ, 5-Fluorouracil, 5-FU, Calciumfolinat, Leucovorin, Oxaliplatin, ELOXATIN, Docetaxel, TAXOTERE
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest, Roche Pharma AG
Gastric Cancer, Gastroesophageal Junction Adenocarcinoma
05/27
12/27
NCT05494697: Ampligen Compared to No Treatment Following FOLFIRINOX in Subjects With Locally Advanced Pancreatic Adenocarcinoma

Recruiting
2
90
US
Rintatolimod, Ampligen, poly I : poly C12U
AIM ImmunoTech Inc., Amarex Clinical Research
Pancreatic Cancer
06/27
07/27
NCT05504720: Evaluating Pembrolizumab, Trastuzumab and FLOT as Perioperative Treatment of HER2-positive, Localized Esophagogastric Adenocarcinoma

Active, not recruiting
2
31
Europe
Pembrolizumab, Keytruda, Trastuzumab, Ontruzant, FLOT
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest, Merck Sharp & Dohme LLC, Organon Healthcare GmbH
Esophagogastric Adenocarcinoma
10/27
12/27
NCT06109467: Neratinib In Combination With Chemotherapy/Trastuzumab/Pembrolizumab In HER2 Gastroesophageal Cancer

Recruiting
2
36
US
Neratinib, NERLYNX, Trastuzumab, Herceptin, Oxaliplatin, Eloxatin, 5-Fluorouracil + leucovorin, Pembrolizumab, Keytruda
H. Lee Moffitt Cancer Center and Research Institute, Puma Biotechnology, Inc., National Comprehensive Cancer Network
GastroEsophageal Cancer, Gastric Cancer
04/28
04/28
IMCODE003, NCT05968326: A Study of the Efficacy and Safety of Adjuvant Autogene Cevumeran Plus Atezolizumab and mFOLFIRINOX Versus mFOLFIRINOX Alone in Participants With Resected Pancreatic Ductal Adenocarcinoma

Recruiting
2
260
Europe, Canada, US
Autogene cevumeran, Atezolizumab, Tecentriq, mFOLFIRINOX
Genentech, Inc., BioNTech SE
Adenocarcinoma, Pancreatic Ductal
12/29
12/29
YY-20394-008, NCT04500561: YY-20394 、GEMOX Treatment Diffuse Large B-cell Lymphoma Single Arm, Open, Multicentrized Phase 1b/2 Clinical Trial

Not yet recruiting
1b/2
28
NA
YY-20394, Gemcitabine, Oxaliplatin
Shanghai YingLi Pharmaceutical Co. Ltd.
Diffuse Large B Cell Lymphoma
10/21
12/21
QUILT-3.071, NCT03563157: QUILT 3.071: NANT Colorectal Cancer (CRC) Vaccine

Active, not recruiting
1b/2
332
US
Aldoxorubicin Hydrochloride, ALT-803, ETBX-011, ETBX-021, ETBX-051, ETBX-061, GI-4000, GI-6207, GI-6301, haNK, Avelumab, Capecitabine, Cetuximab, Cyclophosphamide, 5-Fluorouracil, Leucovorin, Nab-paclitaxel, Oxaliplatin, Regorafenib, SBRT
ImmunityBio, Inc.
Colorectal Cancer Metastatic, mCRC
12/22
12/22
2012-003678-13: Phase I-II trial of gemcitabine plus nab-paclitaxel (GemBrax) followed by FOLFIRINOX as first-line treatment of patients with metastatic pancreatic adenocarcinoma

Not yet recruiting
1/2
118
Europe
Powder for suspension for injection, Powder for solution for infusion, Solution for infusion, Solution for injection, ABRAXANE, GEMCITABINE, OXALIPATINE, CAMPTO, FOLINATE DE CALCIUM, FLUOROURACILE
Institut Régional de Cancerologie de Montpellier - Val d’Aurelle, Laboratory CELGENE
metastatic pancreatic adenocarcinoma, Pancreatic cancer, Diseases [C] - Cancer [C04]
 
 
2013-004385-34: Activity of Regorafenib in combination with modified Gemcitabine - Oxaliplatin Chemotherapy (mGEMOX) in patients with advanced Biliary Tract Cancer (BTC): A Phase Ib-II trial

Not yet recruiting
1/2
87
Europe
Coated tablet, Powder for solution for infusion, STIVARGA, GEMCITABINE, OXALIPLATINE
Institut régional du Cancer - Montpellier - Val d'Aurelle, Institut régional du Cancer - Montpellier - Val d'Aurelle
advanced Biliary Tract Cancer, Biliary Cancer, Diseases [C] - Cancer [C04]
 
 
NCT01959139: S1313, PEGPH20 in Treating Patients With Newly Diagnosed Metastatic Pancreatic Cancer

Completed
1/2
126
US
PEGPH20, Pegylated Recombinant Human Hyaluronidase, Oxaliplatin, Eloxatin, NSC-266046, Leucovorin, leucovorin calcium, Irinotecan, CPT-11, NSC-616348, 5-fluorouracil, 5-FU, Adrucil, NSC-19893
SWOG Cancer Research Network, National Cancer Institute (NCI), Halozyme Therapeutics
Metastatic Pancreatic Adenocarcinoma
04/19
11/23
2019-003727-38: MEN1611 in Colorectal Cancer

Ongoing
1/2
44
Europe
MEN1611, Cetuximab, MEN1611, Cetuximab, Capsule, Solution for solution for infusion, Erbitux 5 mg/mL solution for infusion
Menarini Ricerche S.p.A., MENARINI RICERCHE SPA, Menarini Ricerche S.p.A.
PIK3CA mutated colorectal cancer, PIK3CA mutated colorectal cancer, Diseases [C] - Cancer [C04]
 
 
2019-004483-22: A study of Trastuzumab Deruxtecan to assess its safety, tolerability, immune response, and inhibition of tumor activity when given alone or in combination with other agents in patients with HER2- expressing Gastric Cancer

Not yet recruiting
1/2
357
Europe
Trastuzumab Deruxtecan, Durvalumab, Capecitabine, 5-Fluorouracil, Oxaliplatin, Trastuzumab, Cisplatin, Pembrolizumab, Volrustomig, DS-8201a, MEDI4736, MEDI5752, Powder for concentrate for solution for infusion, Concentrate for solution for infusion, Film-coated tablet, Solution for infusion, Keytruda 25 mg/mL concentrate for solution for infusion
AstraZeneca AB, ASTRAZENECA AB, AstraZenecaAB, AstraZeneca AB
Patients with Human Epidermal Growth Factor Receptor 2 (HER2)-expressing gastric, GEJ and esophageal cancer, Patients with HER2-expressing gastric, GEJ and esophageal cancer, Diseases [C] - Cancer [C04]
 
 
ZUMA-1, NCT02348216 / 2015-005007-86: Study Evaluating the Safety and Efficacy of KTE-C19 in Adult Participants With Refractory Aggressive Non-Hodgkin Lymphoma

Checkmark Data from ZUMA-1 trial for R/R LBCL at ASH 2022
Dec 2022 - Dec 2022: Data from ZUMA-1 trial for R/R LBCL at ASH 2022
Checkmark Presentation from ZUMA-1 trial for DLBCL at ASTCT 2021
Feb 2021 - Feb 2021: Presentation from ZUMA-1 trial for DLBCL at ASTCT 2021
Checkmark Presentation from ZUMA-1 trial for DLBCL at ASH 2020
More
Completed
1/2
307
Europe, Canada, US, RoW
Axicabtagene Ciloleucel, Yescarta®, Fludarabine, Cyclophosphamide, Levetiracetam, Tocilizumab, Dexamethasone, High-dose methylprednisolone, Bendamustine, Rituximab, Doxorubicin, Prednisone, Vincristine, Ifosfamide, Carboplatin, Etoposide, Gemcitabine, Oxaliplatin, Cisplatin, Methylprednisolone
Kite, A Gilead Company
Refractory Diffuse Large B Cell Lymphoma (DLBCL), Relapsed Diffuse Large B-Cell Lymphoma, Transformed Follicular Lymphoma (TFL), Primary Mediastinal B-cell Lymphoma (PMBCL), High Grade B-cell Lymphoma (HGBCL)
07/23
07/23
2020-005182-14: A clinical study investigating the safety and effect of a potential new therapy mitazalimab in combination with standard chemotherapy treatment in patients with pancreatic cancer

Not yet recruiting
1/2
80
Europe
mitazalimab, Oxaliplatin, Leucovorin, Irinotecan, Flurouracil, Gemcitabine, Abraxane, Eloxatine, Calcium Folinate Zentiva, Campto, Flurouracil Teva, Gemcitabine Accord, Abraxane, Powder for concentrate for solution for infusion, Concentrate for solution for infusion, Solution for injection/infusion, Powder for solution for injection/infusion
Alligator Bioscience AB, Alligator Bioscience AB
Metastatic Pancreatic Ductal Adenocarcinoma adénocarcinome canalaire pancréatique en phase métastatique, Pancreatic Cancer Cancer du pancréas, Diseases [C] - Cancer [C04]
 
 
2020-002791-13: A Phase I open label followed by a Phase II randomized, controlled study to assess the efficacy and safety of ABTL0812 in combination with FOLFIRINOX for first-line treatment of metastatic pancreatic cancer

Not yet recruiting
1/2
144
Europe
ABTL0812, ABTL0812, Oral solution
Ability Pharmaceuticals, SL, Ability Pharmaceuticals, SL
Metastatic pancreatic cancer, Pancreatic cancer, Diseases [C] - Cancer [C04]
 
 
NCT02671435 / 2016-000662-38: A Study of Durvalumab (MEDI4736) and Monalizumab in Solid Tumors

Hourglass Jan 2021 - Dec 2022 : From trial in combination with monalizumab for solid tumors
Hourglass Jan 2021 - Dec 2021 : Data from P2 expansion cohort 3 of P1/2 trial in combination with monalizumab and cetuximab for SCCHN
Checkmark Combination trial with monalizumab at ASCO 2018 [screenshot]
Jun 2018 - Jun 2018: Combination trial with monalizumab at ASCO 2018 [screenshot]
Checkmark Combination study with NKG2A
More
Active, not recruiting
1/2
383
Europe, Canada, US, RoW
Monalizumab, Durvalumab, Cetuximab, mFOLFOX6, Bevacizumab
MedImmune LLC
Advanced Solid Tumors
10/21
09/24
IPLUS, NCT03618758: Intraperitoneal Paclitaxel Plus Systemic mFOLFOX6

Completed
1/2
35
RoW
Paclitaxel, (Genexol®), mFOLFOX6 regimen
Seoul National University Bundang Hospital, Boryung Pharmaceutical Co., Ltd, B. Braun Korea Co., Ltd.
Gastric Cancer Stage IV, Peritoneal Carcinomatosis, Intraperitoneal Paclitaxel, mFOLFOX6
08/23
12/23
NCT04228601: A Study of Fluzoparib in Combination With mFOLFIRINOX in Patients With Advanced Pancreatic Cancer

Recruiting
1/2
66
RoW
Fluzoparib, SHR3162, Fluzoparib placebo, mFOLFIRINOX
Jiangsu HengRui Medicine Co., Ltd.
Advanced Pancreatic Cancer
08/22
02/23
HLX07Ib/II, NCT03577704: The Safety,Efficacy of Anti-EGFR Humanized Monoclonal Antibody Combined With Chemotherapy in Advanced Solid Tumors.

Completed
1/2
56
RoW
HLX07+Gemcitabine+Cisplatin, Recombinant anti-EGFR humanized monoclonal antibody, Gemzar, Cisplatin, HLX07+Paclitaxel+Carboplatin, Paclitaxel, Carboplatin, HLX07+mFOLFOX6, Oxaliplatin for Injection, Folinic acid calcium salt hydrate, 5-fluouracil
Shanghai Henlius Biotech
Advanced Solid Tumors
09/22
12/22
COLUMBIA 1, NCT04068610: COLUMBIA-1: Novel Oncology Therapies in Combination With Chemotherapy and Bevacizumab as First- Line Therapy in MSS-CRC

Terminated
1/2
61
Europe, Canada, US, RoW
Durvalumab, MEDI4736, Oleclumab, MEDI9447, FOLFOX, Bevacizumab
MedImmune LLC
Metastatic Microsatellite-stable Colorectal Cancer
10/22
10/22
NCT03761914: Galinpepimut-S in Combination With Pembrolizumab in Patients With Selected Advanced Cancers

Active, not recruiting
1/2
90
US
galinpepimut-S, SLS-001, GPS, WT1 Analog Peptide Vaccine, Pembrolizumab, MK-3475, Keytruda
Sellas Life Sciences Group, Merck Sharp & Dohme LLC, Cancer Insight, LLC
Acute Myelogenous Leukemia, Ovarian Cancer, Colorectal Cancer, Triple-negative Breast Cancer, Small-cell Lung Cancer
11/22
04/23
AK117-204, NCT05235542: A Phase Ib/II Study of AK104 and AK117 in Combination With or Without Chemotherapy in Advanced Malignant Tumors

Recruiting
1/2
130
RoW
AK104, AK117, Capecitabine tablets, Oxaliplatin, Cisplatin, Paclitaxel, Irinotecan, Docetaxel, 5-FU
Akeso
Advanced Malignant Tumors
03/23
03/24
NCT05116891: A Phase 1/2 Study of CAN04 in Combination With Different Chemotherapy Regimens in Subjects With Advanced Solid Tumors

Completed
1/2
40
Europe
CAN04 (nadunolimab), nadumolimab, mFOLFOX, Modified Folfox; Oxaliplatin, 5-fluorouracil (5-FU), leucovorin, DTX, Docetaxel, G/C, Gemcitabine and cisplatin
Cantargia AB
Advanced Solid Tumors, Colorectal Cancer, Non Small Cell Lung Cancer, Biliary Tract Cancer
06/23
06/23
SYS-CAPLIOX, NCT04701281: Study of Intra-Arterial Oxaliplatin Plus Capecitabine to Treat Liver Metastases From Colorectal Cancer

Recruiting
1/2
95
RoW
Intra-arterial LIOX + Capecitabine
AllVascular
Liver Metastasis Colon Cancer
07/23
07/23
COMPASSION-03, NCT03852251: A Study of AK104, a PD-1/CTLA-4 Bispecific Antibody, for Advanced Solid Tumors or With mXELOX/XELOX as First-line Therapy for Advanced Gastric or GEJ Adenocarcinoma

Active, not recruiting
1/2
338
RoW
AK104, Oxaliplatin, Capecitabine
Akeso, Akeso Pharmaceuticals, Inc.
Gastric Adenocarcinoma, Advanced Solid Tumors, Gastroesophageal Junction Adenocarcinoma
08/23
08/23
TWINPEAK, NCT05482893: PT886 For Treatment of Patients With Metastatic/Advanced Gastric, Gastroesophageal Junction and Pancreatic Adenocarcinoma (the Study)

Recruiting
1/2
114
US
PT886, Paclitaxel, Gemcitabine, Abraxane, KEYTRUDA® (pembrolizumab), Oxaliplatin, Leucovorin, Fluorouracil, Capecitabine
Phanes Therapeutics, Merck Sharp & Dohme LLC
Gastric or Gastroesophageal Junction Adenocarcinoma, Pancreatic Ductal Adenocarcinoma
12/25
04/26
C-PRECISE-01, NCT04495621 / 2019-003727-38: MEN1611 With Cetuximab in Metastatic Colorectal Cancer

Completed
1/2
29
Europe, US
MEN1611, Cetuximab
Menarini Group, Menarini Ricerche S.p.A.
Metastatic Colorectal Cancer
01/24
02/24
BGB-A317-ZW25-101, NCT04276493: Anti-HER2 Bispecific Antibody ZW25 Activity in Combination With Chemotherapy With/Without Tislelizumab

Active, not recruiting
1/2
71
RoW
ZW25, Docetaxel, Tislelizumab, BGB-A317, Capecitabine, Oxaliplatin
BeiGene
Breast Cancer, Gastric Cancer, Gastroesophageal Junction Cancer
12/23
12/26
TranStar102, NCT04495296: A Trial to Evaluate Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of TST001 in Advanced or Metastatic Solid Tumors

Recruiting
1/2
320
RoW
TST001, Oxaliplatin, Capecitabine, Paclitaxel, Gemcitabine, Cisplatin, Nivolumab
Suzhou Transcenta Therapeutics Co., Ltd., Bristol-Myers Squibb
Advanced Cancer
08/24
11/24
TOUCH, NCT04425070: A Study of Evaluating the Safety and Efficacy of ATG-010 Combined With Chemotherapy Sequential With ATG-010 Monotherapy Maintenance in Peripheral T- and NK/T-cell Lymphoma

Hourglass Dec 2022 - Dec 2022 : First-patient-in of ARM-C of TOUCH trial in combination with tislelizumab for r/r/ peripheral T- and NK/T-cell lymphoma
Checkmark Data from TOUCH trial for r/r peripheral T- and NK/T-cell lymphoma
Nov 2022 - Nov 2022: Data from TOUCH trial for r/r peripheral T- and NK/T-cell lymphoma
Checkmark Presentation of data from TOUCH trial for the treatment of NK - Cell lymphoma at ASH 2021
Dec 2021 - Dec 2021: Presentation of data from TOUCH trial for the treatment of NK - Cell lymphoma at ASH 2021
Active, not recruiting
1/2
56
RoW
ICE [ifosfamide+carboplatin+etoposide], GEMOX [gemcitabine+oxaliplatin], Tislelizumab
Antengene Corporation
Peripheral T-cell Lymphoma, NK/T-cell Lymphoma
12/24
12/24
HERIZON, NCT02795988: A Study of IMU-131(HER-Vaxx) and Chemotherapy Compared to Chemotherapy Only in Patients With HER2 Positive Advanced Gastric Cancer

Active, not recruiting
1/2
36
RoW
IMU-131, HER-Vaxx, Cisplatin and either Fluorouracil (5-FU) or Capecitabine or Oxaliplatin and capecitabine., Standard of Care Chemotherapy
Imugene Limited
Gastrointestinal Neoplasms, Adenocarcinoma
03/24
08/24
NCT02826837: LEAC-102 for Advanced Colorectal Cancer

Not yet recruiting
1/2
30
NA
LEAC-102 500mg capsule and FOLFOX + Bevacizumab/Cetuximab
Taiwan Leader Biotech Corp.
Advanced Colorectal Cancer
02/24
02/24
ONC001, NCT04393298: A Study to Assess the Safety, Pharmacokinetics and Anti Tumor Activity of UCB6114 Administered Intravenously to Participants With Advanced Solid Tumors

Completed
1/2
95
Europe, US
ginisortamab, UCB6114, trifluridine/tipiracil, TAS-102, Lonsurf®, mFOLFOX6, Calcium folinate, 5-FU, fluorouracil
UCB Biopharma SRL
Advanced Solid Tumors
04/24
04/24
NCT04807972 / 2020-005767-31: Study to Evaluate Adverse Events and Change in Disease Activity When Intravenous (IV) Infusion of ABBV-927 is Administered in Combination With IV Modified FOLFIRINOX (mFFX) With or Without IV Budigalimab Compared to mFFX in Adult Participants With Untreated Pancreatic Cancer Metastasis

Completed
1/2
40
Europe, US, RoW
ABBV-927, Budiglimab, ABBV-181, modified FOLFIRINOX, mFFX
AbbVie
Pancreatic Cancer
03/24
03/24
REGONIVOCTx, NCT05394740: Clinical Study of Regorafenib and Nivolumab Plus Chemotherapy

Active, not recruiting
1/2
30
Japan
Regorafenib, Stivarga, Nivolumab, Opdivo, CapeOX, XELOX, Capecitabine and Oxaliplatin, FOLFOX regimen, Leucovorin, Fluorouracil and Oxaliplatin
National Cancer Center Hospital East, Bayer Yakuhin, Ltd.
Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Esophageal Adenocarcinoma
05/24
11/25
OrigAMI-1, NCT05379595: A Study of Amivantamab Monotherapy and in Addition to Standard-of-Care Chemotherapy in Participants With Advanced or Metastatic Colorectal Cancer

Recruiting
1/2
225
Europe, Canada, US, RoW
Amivantamab, RYBREVANT, JNJ-61186372, Fluorouracil, Leucovorin, Oxaliplatin, Irinotecan
Janssen Research & Development, LLC
Advanced or Metastatic Colorectal Cancer
04/27
04/27
NCT05846867: Study of AK119 and AK 112 With or Without Chemotherapy for Colorectal Cancer Patients

Not yet recruiting
1/2
72
RoW
AK119, AK112, Oxaliplatin, Irinotecan, Calcium folinate, Fluorouracil
Akeso
Colorectal Cancer
05/24
07/25
NCT06445062: Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors

Recruiting
1/2
406
US
RMC-6236, mFOLFOX6 regimen, bevacizumab, mFOLFIRINOX regimen, cetuximab, gemcitabine, nab-paclitaxel
Revolution Medicines, Inc.
Colorectal Cancer, CRC, Pancreatic Ductal Adenocarcinoma, PDAC, Gastrointestinal Cancer, Metastatic Pancreatic Ductal Adenocarcinoma
05/27
07/27
SGNTUC 024, NCT04430738: Tucatinib Plus Trastuzumab and Oxaliplatin-based Chemotherapy or Pembrolizumab-containing Combinations for HER2+ Gastrointestinal Cancers

Recruiting
1/2
40
Japan, US
tucatinib, TUKYSA, trastuzumab, oxaliplatin, leucovorin, fluorouracil, capecitabine, pembrolizumab, KEYTRUDA
Seagen Inc.
Colorectal Carcinoma, Gastric Adenocarcinoma, GEJ Adenocarcinoma, Esophageal Adenocarcinoma, Cholangiocarcinoma, Gallbladder Carcinoma
03/25
10/25
TransStar101, NCT04396821: A Trial to Evaluate Safety and Tolerability of TST001 in Advanced or Metastatic Solid Tumors

Recruiting
1/2
150
US
TST001, Nivolumab Injection [Opdivo], mFOLFOX6, Gemcitabine, Gemzar, Albumin-Bound Paclitaxel
Suzhou Transcenta Therapeutics Co., Ltd., Bristol-Myers Squibb
Advanced Cancer, Gastric Cancer, Gastroesophageal-junction Cancer, Pancreatic Cancer
06/24
12/24
NCT06469944: Substudy 06C: A Study of Sacituzumab Tirumotecan (MK-2870) With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06)

Not yet recruiting
1/2
130
NA
Pembrolizumab, MK-3475, Keytruda®, Sacituzumab Tirumotecan, MK-2870, SKB264, Capecitabine, XELODA, Leucovorin, calcium folinate, folinic acid, WELLCOVORIN®, Levoleucovorin, calcium levofolinate, levofolinic acid, FUSILEV®, 5-FU, ADRUCIL®
Merck Sharp & Dohme LLC
Gastroesophageal Junction, Gastroesophageal Adenocarcinoma, Esophageal Neoplasms, Esophageal Cancer
01/27
04/29
 

Download Options